Striving Toward Hepatitis C Elimination in the Era of COVID-19

Hochstatter K, Akhtar W, Dietz S, Pe-Romashko K, Gustafson D, Shah D . Potential Influences of the COVID-19 Pandemic on Drug Use and HIV Care Among People Living with HIV and Substance Use Disorders: Experience from a Pilot mHealth Intervention. AIDS Behav. 2020; 25(2):354-359. PMC: 7376523. DOI: 10.1007/s10461-020-02976-1. View

Bartholomew T, Nakamura N, Metsch L, Tookes H . Syringe services program (SSP) operational changes during the COVID-19 global outbreak. Int J Drug Policy. 2020; 83:102821. PMC: 7290194. DOI: 10.1016/j.drugpo.2020.102821. View

Slavova S, Rock P, Bush H, Quesinberry D, Walsh S . Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020; 214:108176. PMC: 7351024. DOI: 10.1016/j.drugalcdep.2020.108176. View

Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M . Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 2019; 40(3):522-529. DOI: 10.1111/liv.14324. View

Wise J . Covid-19: Risk of second wave is very real, say researchers. BMJ. 2020; 369:m2294. DOI: 10.1136/bmj.m2294. View

Glick S, Prohaska S, LaKosky P, Juarez A, Corcorran M, Des Jarlais D . The Impact of COVID-19 on Syringe Services Programs in the United States. AIDS Behav. 2020; 24(9):2466-2468. PMC: 7182093. DOI: 10.1007/s10461-020-02886-2. View

Tyndall M . Safer opioid distribution in response to the COVID-19 pandemic. Int J Drug Policy. 2020; 83:102880. PMC: 7383133. DOI: 10.1016/j.drugpo.2020.102880. View

Serper M, Cubell A, Deleener M, Casher T, Rosenberg D, Whitebloom D . Telemedicine in Liver Disease and Beyond: Can the COVID-19 Crisis Lead to Action?. Hepatology. 2020; 72(2):723-728. PMC: 7262294. DOI: 10.1002/hep.31276. View

Chang J, Agliata J, Guarinieri M . COVID-19 - Enacting a 'new normal' for people who use drugs. Int J Drug Policy. 2020; 83:102832. PMC: 7332951. DOI: 10.1016/j.drugpo.2020.102832. View

10.

Binka M, Janjua N, Grebely J, Estes C, Schanzer D, Kwon J . Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model. JAMA Netw Open. 2020; 3(5):e204192. PMC: 7203608. DOI: 10.1001/jamanetworkopen.2020.4192. View

11.

Whitfield M, Reed H, Webster J, Hope V . The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England. Int J Drug Policy. 2020; 83:102851. PMC: 7362866. DOI: 10.1016/j.drugpo.2020.102851. View

12.

Jacka B, Phipps E, Marshall B . Drug use during a pandemic: Convergent risk of novel coronavirus and invasive bacterial and viral infections among people who use drugs. Int J Drug Policy. 2020; 83:102895. PMC: 7388892. DOI: 10.1016/j.drugpo.2020.102895. View

13.

Guise A, Witzel T, Mandal S, Sabin C, Rhodes T, Nardone A . A qualitative assessment of the acceptability of hepatitis C remote self-testing and self-sampling amongst people who use drugs in London, UK. BMC Infect Dis. 2018; 18(1):281. PMC: 6006927. DOI: 10.1186/s12879-018-3185-7. View

14.

Blach S, Kondili L, Aghemo A, Cai Z, Dugan E, Estes C . Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2020; 74(1):31-36. PMC: 7411379. DOI: 10.1016/j.jhep.2020.07.042. View

15.

Vasylyeva T, Smyrnov P, Strathdee S, Friedman S . Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks. J Int AIDS Soc. 2020; 23(7):e25583. PMC: 7375066. DOI: 10.1002/jia2.25583. View